Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ziltivekimab - Corvidia Therapeutics

Drug Profile

Ziltivekimab - Corvidia Therapeutics

Alternative Names: COR 001

Latest Information Update: 24 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Corvidia Therapeutics
  • Class Anti-inflammatories; Monoclonal antibodies; Urologics
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cardiovascular disorders

Most Recent Events

  • 16 Nov 2019 Efficacy data from a phase I/II trial in Cardiovascular disorders presented at the American Heart Association Scientific Sessions 2019 (AHA-2019)
  • 03 Jun 2019 Corvidia Therapeutics initiates a phase II RESCUE trial for Cardiovascular disorders in USA (NCT03926117)
  • 24 Apr 2019 Corvidia Therapeutics plans the phase II RESCUE trial for Inflammation in USA in June 2019 (SC) (NCT03926117)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top